Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia

Schizophrenia Research

Volumn 30, Issue 1, 1998, Pages 91-99

  Mohr, Pavel ^a,b   Horáček, Jiří ^a   Motlová, Lucie ^a   Libiger, Jan ^a   Czobor, Pál ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

D fenfluramine challenge; Prolactin; Schizophrenia; Serotonin; Treatment response

Indexed keywords

DEXFENFLURAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; PROLACTIN; SEROTONIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROVOCATION TEST; RATING SCALE; SCHIZOPHRENIA; TIME; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; FEMALE; FENFLURAMINE; HALOPERIDOL; HUMANS; MALE; PROLACTIN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 0032570653     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(97)00124-2     Document Type: Article

References (40)

1. Abel, K.M., O'Keane, V., Murray, R.M., 1996. Enhancement of the prolactin response to D-fenfluramine in drug-naïve schizophrenic patients. Br. J. Psychiatry 168, 57-60.
2. Abi-Dargham, A., Laruelle, M., Aghajanian, G.K., Charney, D., Krystal, J., 1997. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 9, 1-17.
3. Baldessarini, R.J., Cohen, B.M., Teicher, M.H., 1988. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 45, 79-91.
4. Benker, G., Jaspers, C., Häusler, G., Reinwein, D., 1990. Control of prolactin secretion. Klinische Wochenschrift 68, 1157-1167.
5. Bleich, A., Brown, S.-L., Kahn, R., van Praag, H.M., 1988. The role of serotonin in schizophrenia. Schizophr. Bull. 14, 297-315.
6. Breier, A., Buchanan, R.W., Kirkpatrick, B., Davis, O.R., Irish, D., Summerfelt, A., Carpenter, W.T., 1994. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 151, 20-26.
7. Breier, A., 1995. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 14, 187-202.
8. Coccaro, E.F., Kavoussi, R.J., 1994. Neuropsychopharmacologic challenge in biological psychiatry. Clin. Chem. 40, 319-327.
9. Coccaro, E.F., Kavoussi, R.J., Cooper, T.B., Hauger, R.L., 1996a. Hormonal responses to D-and D,Osl-fenfluramine in healthy human subjects. Neuropsychopharmacology 15, 595-607.
10. 2a/2c receptor blockade by amesergide fully attenuates prolactin response to D-fenfluramine challenge in physically healthy human subjects. Psycho pharmacology 126, 24-30.
11. 3 receptor antagonism by ondansetron does not attenuate prolactin response to D-fenfluramine challenge in healthy human subjects. Psychopharmacology 127, 108-112.
12. Curtis, V.A., Wright, P., Reveley, A., Kerwin, R., Lucey, J.V., 1995. Effect of clozapine on D-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br. J. Psychiatry 166, 642-646.
13. Davis, R., Faulds, D., 1996. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 52, 696-724.
14. Feeney, S., Goodall, F., Silverstone, T., 1993. The prolactin response to D-and L-fenfluramine and to D-amphetamine in human subjects. Int. Clin Psychopharmacology 8, 49-54.
15. Fuxe, K., Farnebo, L.-O., Hamberger, B., Ögren, S.-O., On the in vivo and in vitro actions of fenfluramine and its derivates on central monoamine neurons, especially 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine. 1975. Postgrad. Med. J. 51 (Suppl. 1), 35-45.
16. Garattini, S., Buczko, W., Jori, A., Samanin, R., 1975. The mechanism of action of fenfluramine. Postgrad. Med. J. 51 (Suppl. 1), 27-35.
17. Garattini, S., Mennini, T., Samanin, R., 1987. From fenfluramine racemate to D-fenfluramine. Ann. N.Y. Acad. Sci. 499, 156-166.
18. Goodall, E.M., Cowan, P.J., Franklin, M., Silverstone, T., 1993. Ritanserin attenuates anorectic. endocrine and thermal responses to D-fenfluramine in human volunteers. Psychopharmacology 112, 461-466.
19. Goodwin, G.M., Murray, C.L., Bancroft, J., 1994. Oral D-fenfluramine and neuroendocrine challenge: problems with the 30 mg dose in men. J. Affect. Dis. 30, 117-122.
20. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology Revised, 1976. National Institute of Mental Health, Rockville, p. 603.
21. Invernizzi, R., Berettera. C., Garattini, S., Samanin, R., 1986. D-and L-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. Eur. J. Pharmacol. 120, 9-15.
22. Invernizzi, R., Bertorelli, R., Consolo. S., Garattini, S., Samanin, R., 1989. Effects of the L = isomer of fenfluramine on dopamine mechanisms in rat brain: further studies. Eur. J. Pharmacol. 164, 241-248.
23. Iqbal, N., van Praag, H.M., 1995. The role of serotonin in schizophrenia. Eur. Neuropsychopharmacol. Suppl., 11-23.
24. Kane, J., Honingfeld, G., Singer, J., Meltzer, H., 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789-796.
25. Marder, S.R., Meibach, R.C., 1994. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151, 825-835.
26. Overall, J.E., Gorham, D.R., 1962. The Brief Psychiatric Rating Scale. Psychol. Rep. 10, 799-812.
27. Park, S.B.G., Cowen, P.J., 1995. Effect on pindolol on the prolactin response to D-fenfluramine. Psychopharmacology 118, 471-474.
28. Peuskens, J., Risperidone Study Group, 1995. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br. J. Psychiatry. 166, 712-726.
29. Quattrone, A., di Renzo, G., Schettini, G., Tedeschi, G., Scopacasa, F., 1978. Increased plasma prolactin levels induced in rats by D-fenfluramine: relation to central serotonergic stimulation. Eur. J. Pharmacol. 49, 163-167.
30. Quattrone, A., Tedeschi, G., Aguglia, U., Scopacasa, F., di Renzo, G.F., Annunziato, L., 1983. Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine. Br. J. Clin. Pharmacol. 16, 471-475.
31. Rifkin, A., Doddi, S., Karajgi, B., Borenstein, M., Wachspress, M., 1991. Dosage of haloperidol for schizophrenia. Arch. Gen. Psychiatry 48, 166-170.
32. Seeman, P., 1980. Brain dopamine receptors. Pharmacol. Rev. 32, 229-313.
33. Shopsin, B., Klein, H., Aaronsom, M., Collora, M., 1979. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. Arch. Gen. Psychiatry 36, 657-664.
34. Small, J.G., Hirsch, S.R., Arvanitis, L.A., Miller, B.C., Link, C.G.G., The Seroquel Study Group, 1997. Quetiapine in patients with schizophrenia. Arch. Gen. Psychiatry, 54, 549-557.
35. Tollefson, G.D., Beasley Jr., C.M., Tran, P.V., Street, J.S., Krueger, J.A., Tamura, R.N., Graffeo, K.A., Thieme, M.E., 1997. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 154, 457-465.
36. van Praag, H.M., Lemus, C., Kahn, R., 1987. Hormonal probes of central serotonergic activity: do they really exist? Biol. Psychiatry 22, 86-98.
37. Volavka, J., Cooper, T.B., Czobor, P., Meisner, M., 1995. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 52, 837-845.
38. World Health Organization, 1993. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. World Health Organization, Geneva, p. 248.
39. Yatham, L.N., Steiner, M., 1993. Neuroendocrine probes of serotonergic function: a critical review. Life Sciences 53. 447-463.
40. Zimbroff, D.L., Kane, J.M., Tamminga, C.A., Daniel, D.G., Mack, R.J., Wozniak, P.J., Sebree, T.B., Wallin, B.A., Kashkin, K.B. & The Sertindole Study Group, 1997. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry 154, 782-791.